{"id":4758,"date":"2021-10-11T10:05:34","date_gmt":"2021-10-11T10:05:34","guid":{"rendered":"https:\/\/cdafound.org\/?page_id=4758"},"modified":"2026-06-01T06:46:52","modified_gmt":"2026-06-01T06:46:52","slug":"activities-and-impacts","status":"publish","type":"page","link":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/activities-and-impacts\/","title":{"rendered":"Activities and Impacts"},"content":{"rendered":"\n

Activities\/\u200bImpacts<\/h2>

Activities<\/h2>

Impacts<\/h2><\/div><\/header>
<\/div>\n

2013<\/h3>
\n
<\/div>\n
<\/div>

Activity<\/h3>
\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Generated HCV Medicines and Diagnostics Report for UNITAID<\/h4>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"Publication<\/figure>\n<\/div>\n\n\n\n
\n

This scoping report focuses on issues, challenges and opportunities related to one of the most important HIV co-infections\u2014Hepatitis C virus (HCV)\u2014and represents UNITAID\u2019s first effort to gather market intelligence on products for the diagnosis and treatment of HCV in individuals co-infected with HIV and HCV.<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>

<\/div>